Tiger Balm marketer earns FDA warning
This article was originally published in The Tan Sheet
Executive Summary
Singapore-based Haw Par Healthcare's Tiger Balm Pain Relieving Patch is a misbranded drug because it makes drug claims such as "stimulating blood circulation" and thus cannot be marketed as an OTC, FDA says. Further, the agency found "significant" violations of good manufacturing practices - including failure to set appropriate specifications - during an inspection of Haw Par's facility, FDA said in a July 20 warning letter
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.